Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Heart Diseases 3Vascular Diseases 2Small Cell Lung Carcinoma 2Leukemia, Myeloid, Acute 2Cardiovascular Diseases 2Cardiotoxicity 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Noonan Syndrome 5 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metabolic Diseases 1Liver Neoplasms 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Immune-related Adverse Event 1Hematologic Neoplasms 1Heart Failure 1Esophageal Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1

Interventions

Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Early Hormone Receptor-positive Breast Cancer × Antineoplastic Agents × Clear all
NCT04278469 2020-02-20

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Gencurix, Inc.

Phase NA Recruiting
194 enrolled
Breast

Early Hormone Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡